tiprankstipranks
Trending News
More News >
Pfizer (DE:PFE)
XETRA:PFE
Germany Market
Advertisement

Pfizer (PFE) Stock Forecast & Price Target

Compare
193 Followers
See the Price Targets and Ratings of:

PFE Analyst Ratings

Hold
18Ratings
Hold
5 Buy
12 Hold
1 Sell
Based on 18 analysts giving stock ratings to
Pfizer
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

PFE Stock 12 Month Forecast

Average Price Target

€24.39
▲(6.05% Upside)
Based on 18 Wall Street analysts offering 12 month price targets for Pfizer in the last 3 months. The average price target is €24.39 with a high forecast of €28.97 and a low forecast of €20.45. The average price target represents a 6.05% change from the last price of €23.00.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"19":"€19","24":"€24","29":"€29","21.5":"€21.5","26.5":"€26.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":28.9659498,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€28.97</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":24.391033611,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€24.39</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20.4465528,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€20.45</span>\n  </div></div>","useHTML":true}}],"tickPositions":[19,21.5,24,26.5,29],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,23,23.458919215384615,23.91783843076923,24.376757646153848,24.835676861538463,25.294596076923078,25.753515292307693,26.212434507692308,26.671353723076923,27.130272938461538,27.589192153846156,28.04811136923077,28.507030584615386,{"y":28.9659498,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,23,23.10700258546154,23.214005170923077,23.321007756384617,23.428010341846154,23.535012927307694,23.64201551276923,23.74901809823077,23.856020683692307,23.963023269153847,24.070025854615384,24.177028440076924,24.28403102553846,{"y":24.391033611,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,23,22.803580984615383,22.60716196923077,22.410742953846153,22.21432393846154,22.017904923076923,21.821485907692306,21.625066892307693,21.428647876923076,21.23222886153846,21.035809846153846,20.83939083076923,20.642971815384616,{"y":20.4465528,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":24.255,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.354,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 37, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.371,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 50, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.097,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 43, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.754,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 41, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.069,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.294,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 49, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.631,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 49, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.156,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 57, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.972,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 39, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.14,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 39, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.19,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 35, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€28.97Average Price Target€24.39Lowest Price Target€20.45
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bank of America Securities Analyst forecast on DE:PFE
Bank of America Securities
Bank of America Securities
€23.85
Hold
3.71%
Upside
Reiterated
10/01/25
Cautious Hold Rating for Pfizer Amid Positive Drug Pricing Deal and Patent Expiration Challenges
TD Cowen Analyst forecast on DE:PFE
TD Cowen
TD Cowen
€25.56
Hold
11.12%
Upside
Reiterated
10/01/25
Pfizer (PFE) Gets a Hold from TD Cowen
Jefferies Analyst forecast on DE:PFE
Jefferies
Jefferies
€28.97
Buy
25.94%
Upside
Reiterated
10/01/25
Pfizer (PFE) Receives a Buy from Jefferies
TR | OpenAI - 4o Analyst forecast on DE:PFE
TR | OpenAI - 4o
TR | OpenAI - 4o
€23€25.56
Buy
11.12%
Upside
Reiterated
10/01/25
AI Generated ArticleAI Generated Article
BMO Capital Analyst forecast on DE:PFE
BMO Capital
BMO Capital
€25.56
Buy
11.12%
Upside
Reiterated
09/30/25
Pfizer's Strategic Acquisitions and Undervalued Position Drive Buy Rating
J.P. Morgan Analyst forecast on DE:PFE
J.P. Morgan
J.P. Morgan
€25.56
Hold
11.12%
Upside
Reiterated
09/30/25
J.P. Morgan Remains a Hold on Pfizer (PFE)
Bernstein
€25.56
Hold
11.12%
Upside
Assigned
09/30/25
Bernstein Remains a Hold on Pfizer (PFE)
Cantor Fitzgerald Analyst forecast on DE:PFE
Cantor Fitzgerald
Cantor Fitzgerald
€20.45
Hold
-11.10%
Downside
Reiterated
09/29/25
Cantor Fitzgerald Keeps Their Hold Rating on Pfizer (PFE)
Leerink Partners Analyst forecast on DE:PFE
Leerink Partners
Leerink Partners
Hold
Reiterated
09/23/25
Leerink Partners Keeps Their Hold Rating on Pfizer (PFE)
Morgan Stanley Analyst forecast on DE:PFE
Morgan Stanley
Morgan Stanley
€28.11
Hold
22.23%
Upside
Reiterated
09/22/25
Pfizer's Strategic Acquisition of Metsera: A Cautious Hold Amid Market Positioning and Regulatory Uncertainty
Goldman Sachs Analyst forecast on DE:PFE
Goldman Sachs
Goldman Sachs
€23
Hold
0.01%
Upside
Reiterated
09/22/25
Goldman Sachs Sticks to Its Hold Rating for Pfizer (PFE)
Wolfe Research Analyst forecast on DE:PFE
Wolfe Research
Wolfe Research
€21.3
Sell
-7.40%
Downside
Reiterated
09/22/25
Pfizer (PFE) Gets a Sell from Wolfe Research
Berenberg Bank Analyst forecast on DE:PFE
Berenberg Bank
Berenberg Bank
€21.3
Hold
-7.40%
Downside
Reiterated
09/17/25
Berenberg Bank Keeps Their Hold Rating on Pfizer (PFE)
Guggenheim Analyst forecast on DE:PFE
Guggenheim
Guggenheim
€28.11
Buy
22.23%
Upside
Reiterated
09/05/25
Guggenheim Keeps Their Buy Rating on Pfizer (PFE)
DZ BANK AG Analyst forecast on DE:PFE
DZ BANK AG
DZ BANK AG
Buy
Reiterated
08/06/25
DZ BANK AG Sticks to Their Buy Rating for Pfizer (PFE)
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bank of America Securities Analyst forecast on DE:PFE
Bank of America Securities
Bank of America Securities
€23.85
Hold
3.71%
Upside
Reiterated
10/01/25
Cautious Hold Rating for Pfizer Amid Positive Drug Pricing Deal and Patent Expiration Challenges
TD Cowen Analyst forecast on DE:PFE
TD Cowen
TD Cowen
€25.56
Hold
11.12%
Upside
Reiterated
10/01/25
Pfizer (PFE) Gets a Hold from TD Cowen
Jefferies Analyst forecast on DE:PFE
Jefferies
Jefferies
€28.97
Buy
25.94%
Upside
Reiterated
10/01/25
Pfizer (PFE) Receives a Buy from Jefferies
TR | OpenAI - 4o Analyst forecast on DE:PFE
TR | OpenAI - 4o
TR | OpenAI - 4o
€23€25.56
Buy
11.12%
Upside
Reiterated
10/01/25
AI Generated ArticleAI Generated Article
BMO Capital Analyst forecast on DE:PFE
BMO Capital
BMO Capital
€25.56
Buy
11.12%
Upside
Reiterated
09/30/25
Pfizer's Strategic Acquisitions and Undervalued Position Drive Buy Rating
J.P. Morgan Analyst forecast on DE:PFE
J.P. Morgan
J.P. Morgan
€25.56
Hold
11.12%
Upside
Reiterated
09/30/25
J.P. Morgan Remains a Hold on Pfizer (PFE)
Bernstein
€25.56
Hold
11.12%
Upside
Assigned
09/30/25
Bernstein Remains a Hold on Pfizer (PFE)
Cantor Fitzgerald Analyst forecast on DE:PFE
Cantor Fitzgerald
Cantor Fitzgerald
€20.45
Hold
-11.10%
Downside
Reiterated
09/29/25
Cantor Fitzgerald Keeps Their Hold Rating on Pfizer (PFE)
Leerink Partners Analyst forecast on DE:PFE
Leerink Partners
Leerink Partners
Hold
Reiterated
09/23/25
Leerink Partners Keeps Their Hold Rating on Pfizer (PFE)
Morgan Stanley Analyst forecast on DE:PFE
Morgan Stanley
Morgan Stanley
€28.11
Hold
22.23%
Upside
Reiterated
09/22/25
Pfizer's Strategic Acquisition of Metsera: A Cautious Hold Amid Market Positioning and Regulatory Uncertainty
Goldman Sachs Analyst forecast on DE:PFE
Goldman Sachs
Goldman Sachs
€23
Hold
0.01%
Upside
Reiterated
09/22/25
Goldman Sachs Sticks to Its Hold Rating for Pfizer (PFE)
Wolfe Research Analyst forecast on DE:PFE
Wolfe Research
Wolfe Research
€21.3
Sell
-7.40%
Downside
Reiterated
09/22/25
Pfizer (PFE) Gets a Sell from Wolfe Research
Berenberg Bank Analyst forecast on DE:PFE
Berenberg Bank
Berenberg Bank
€21.3
Hold
-7.40%
Downside
Reiterated
09/17/25
Berenberg Bank Keeps Their Hold Rating on Pfizer (PFE)
Guggenheim Analyst forecast on DE:PFE
Guggenheim
Guggenheim
€28.11
Buy
22.23%
Upside
Reiterated
09/05/25
Guggenheim Keeps Their Buy Rating on Pfizer (PFE)
DZ BANK AG Analyst forecast on DE:PFE
DZ BANK AG
DZ BANK AG
Buy
Reiterated
08/06/25
DZ BANK AG Sticks to Their Buy Rating for Pfizer (PFE)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Pfizer

1 Month
xxx
Success Rate
14/27 ratings generated profit
52%
Average Return
-0.07%
reiterated a xxx
rating 3 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 51.85% of your transactions generating a profit, with an average return of -0.07% per trade.
3 Months
xxx
Success Rate
24/35 ratings generated profit
69%
Average Return
+2.79%
reiterated a xxx
rating 28 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 68.57% of your transactions generating a profit, with an average return of +2.79% per trade.
1 Year
Vamil DivanGuggenheim
Success Rate
25/35 ratings generated profit
71%
Average Return
+4.65%
reiterated a buy rating 28 days ago
Copying Vamil Divan's trades and holding each position for 1 Year would result in 71.43% of your transactions generating a profit, with an average return of +4.65% per trade.
2 Years
xxx
Success Rate
25/35 ratings generated profit
71%
Average Return
+6.99%
reiterated a xxx
rating 28 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 71.43% of your transactions generating a profit, with an average return of +6.99% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

PFE Analyst Recommendation Trends

Rating
Jun 25
Jul 25
Aug 25
Sep 25
Oct 25
Strong Buy
2
0
0
0
0
Buy
15
10
11
12
14
Hold
57
39
39
35
25
Sell
0
0
0
1
1
Strong Sell
0
0
0
0
0
total
74
49
50
48
40
In the current month, PFE has received 14 Buy Ratings, 25 Hold Ratings, and 1 Sell Ratings. PFE average Analyst price target in the past 3 months is 24.39.
Each month's total comprises the sum of three months' worth of ratings.

PFE Financial Forecast

PFE Earnings Forecast

Next quarter’s earnings estimate for PFE is €0.62 with a range of €0.54 to €0.82. The previous quarter’s EPS was €0.66. PFE beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year PFE has Preformed in-line its overall industry.
Next quarter’s earnings estimate for PFE is €0.62 with a range of €0.54 to €0.82. The previous quarter’s EPS was €0.66. PFE beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year PFE has Preformed in-line its overall industry.

PFE Sales Forecast

Next quarter’s sales forecast for PFE is €14.59B with a range of €14.06B to €15.24B. The previous quarter’s sales results were €12.48B. PFE beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year PFE has Preformed in-line its overall industry.
Next quarter’s sales forecast for PFE is €14.59B with a range of €14.06B to €15.24B. The previous quarter’s sales results were €12.48B. PFE beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year PFE has Preformed in-line its overall industry.

PFE Stock Forecast FAQ

What is DE:PFE’s average 12-month price target, according to analysts?
Based on analyst ratings, Pfizer’s 12-month average price target is 24.39.
    What is DE:PFE’s upside potential, based on the analysts’ average price target?
    Pfizer has 6.05% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Pfizer a Buy, Sell or Hold?
          Pfizer has a consensus rating of Hold, which is based on 5 buy ratings, 12 hold ratings and 1 sell ratings.
            What is Pfizer’s share price target?
            The average share price target for Pfizer is 24.39. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €28.97 ,and the lowest forecast is €20.45. The average share price target represents 6.05% Increase from the current price of €23.
              What do analysts say about Pfizer?
              Pfizer’s analyst rating consensus is a Hold. This is based on the ratings of 18 Wall Streets Analysts.
                How can I buy shares of Pfizer?
                To buy shares of DE:PFE, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis